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A B S T R A C T
PEGylated liposomes are potential candidates to improve the pharmacokinetic character-
istics of encapsulated drugs, to extend their circulation half-life and facilitate their passive
accumulation at tumour sites. However, PEG-modified liposomes can induce accelerated blood
clearance (ABC) upon repeated administration, and the extent of ABC phenomenon on the
cytotoxic drugs-containing PEGylated liposomes is related to the dose of the cytotoxic drugs.
In this study, EPI served as a model cytotoxic drug, a hydrophilic surfactant molecule,
monosialylganglioside (GM1) was chosen and modified on the liposomes together with PEG.
It was shown that upon mixed modification, when GM1 contents reached 10% or 15% mol,
the ABC phenomenon of the PEGylated liposomal EPI significantly reduced.We also found
that GM1 played an important role in abrogating the ABC phenomenon in both the induc-
tion phase and the effectuation phase. The results suggested that GM1 incorporation
unfortunately did not avoid occurrence of ABC phenomenon completely, but GM1 modifi-
cation on PEGylated liposomes may provide a significant improvement in clinical practice
of PEGylated liposomes. Further study must be necessary.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Liposomes, representing the clinically approved nanomedicine
systems, are well-characterized, simple, and versatile plat-
forms for the manufacture of functional and tuneable drug
carriers [1,2]. However, it was found that conventional lipo-
somes underwent massive uptake readily by the mononuclear
phagocyte system (MPS), which limited the targeting effect of
drugs to the therapeutic sites in vivo [3]. PEGylated nanocarriers
are potential candidates to improve the pharmacokinetic char-
acteristics of encapsulated drugs and to extend their circulation
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half-life for better therapeutic efficacy [4]. Nevertheless, Dams
et al. [5] reported that when PEG-modified liposomes were re-
peatedly injected intravenously in the same animal (with an
interval of several days), it resulted in the loss of the long cir-
culating characteristic and extensive accumulation in the liver
and spleen, and this phenomenon is called “accelerated blood
clearance (ABC) phenomenon”.
Interestingly, the repeated administration of Doxil®, a
PEGylated liposomal formulation of the cytotoxic drug doxo-
rubicin (DXR), within the dose range of 10–60 mg/m2 in clinical
practice did not induce the ABC phenomenon [6], which may
be due to the drug’s cytotoxicity on splenic marginal zone B
cells. However, Suzuki et al. [7] recently reported that Doxil®,
at lower doses (less than 2 mg DXR/m2), induced severe ABC
phenomenon in the beagle dog. Upon repeated administra-
tion of DXR-containing PEGylated liposomes, different results
were attributed to the amount of anti-PEG IgM production.The
IgM producers, proliferating splenic B cells, were inhibited and/
or killed because of the toxicity of DXR released from the first
injected liposomes.
Meanwhile, a novel treatment regimen of sequential low-
dose chemotherapy, termed “metronomic” chemotherapy, has
been broadly applied, in particular, when combined with ra-
diation therapy andanti-angiogenic agents in recent years [8–10].
In contrast with conventional chemotherapy, thismethod dra-
matically reduces the toxic side effects, and decreases the risk
of multidrug resistance by tumour cells [11]. Our group pre-
viously examined the effect of the sequential administration
of PEGylated liposomal epirubicin (EPI) on the induction of the
ABC phenomenon.We demonstrated that the first or sequen-
tial injections of PEGylated liposomal EPI within a certain range
(0.08–1.20 mg epirubicin/kg) inWistar rats induced an instant
clearance of subsequently injected PEGylated liposomal EPI,
leading to the abolishment of its therapeutic efficacy [12].The
induction of the ABC phenomenon upon repeated adminis-
tration of PEGylated liposomes will hinder the development
of sequential low-dose regimen. For cytotoxic drugs, the ABC
phenomenon could cause cumulative damage in theMPSorgans
such as the liver and spleen.These results mean that the ABC
phenomenonwill exist or cannot be negligible when the lower
dose of the cytotoxic drugs containing PEGylated liposomes are
administrated, which will alter the pharmacokinetics of the
liposomal preparations in vivo.
The mechanism that induces the ABC phenomenon has
been extensively evaluated, but is still unclear. At present, the
ABC phenomenon is divided into two phases, the induction
phase and the effectuation phase. During the induction phase,
the first injection of PEGylated liposomes acts as TI-2 anti-
gens and induces an immunological response by tightly cross-
linking to the cell surface immunoglobulins of specific B cells,
resulting in increased anti-PEG IgM production [13,14]. In the
effectuation phase, following the second injection, the pro-
duced anti-PEG IgM selectively binds with the PEG on the
liposomes, and subsequently activates the complement system,
which in turn leads to opsonization by C3 fragments, and en-
hances the uptake by Kupffer cells endocytosis [15,16].
Meanwhile, recent studies also have shown that the connect-
ing portion between the hydrophilic PEG chain and the
hydrophobic segment of the PEG-conjugates such as PEG–
distearoylphosphatidylethanolamine (PEG–DSPE), may be the
key site for anti-PEG IgM to distinguish, which mediates the
ABC [17].
Considering the above factors, we could choose a hydro-
philic surfactant molecule and modify it on the liposomes
together with PEG. On one hand, the mixed modification would
regulate the neat conformation of the PEGmoiety on the surface
of the PEGylated liposomes, resulting in disturbing the pro-
duction of anti-PEG IgM in the induction phase. On the other
hand, the hydrophilic surfactant molecule could mask the hy-
drophobic connecting portion of the PEG–DSPE on the modified
liposomes in the effectuation phase, and thereby, abrogate or
attenuate the ABC phenomenon.
Monosialylganglioside (GM1) is a widely used hydrophilic
surfactant molecule, which has inherent biodegradability and
non-immunogenicity and is found on cell membrane in vivo
[18]. GM1 consists of a hydrophobic “tail”, inserted in the mem-
brane lipid bilayer, and a hydrophilic “head” of oligosaccharide
sugar, mainly including the D-glucose (Glc), D-galactose (Gal),
N-acetylgalactosamine (GalNAc), N-acetylneuraminic acid
(NeuNAc, sialic acid), and N-hydroxy-acetylneuraminic acid
[18,19]. Several studies have attempted to explore the immune
camouflage potential of GM1. In order to increase the blood
circulation time, liposomes were coated with GM1 to imitate
erythrocytes [20]. Gabizon and Papahadjopoulos [21] reported
that GM1-modified liposomes induced a 3.4-fold decrease in
the MPS uptake compared with conventional liposomes after
intravenous injection in mice. Liu et al. [22] showed that GM1-
modified liposomes could escapeMPS uptake.Thus, GM1, a non-
immunogenic and biodegradable material, may have the
potential function to abrogate or attenuate the ABC phenom-
enon of the PEGylated formulation.
In the present study, EPI served as a model cytotoxic drug,
a commonly used anthracycline antitumour antibiotic, and GM1,
at various molar concentrations, wasmodified on the PEGylated
liposomes encapsulating EPI. The purpose was to verify the
effect of GM1 on abrogating or attenuating the ABC phenom-
enon caused by PEGylated liposomes, such as their
pharmacokinetic behaviour and tissue distribution after the
second injection in rats. The findings may provide a solution
to the undesirable immune response, and have a great sig-
nificance in clinical practice of PEGylated liposomes.
2. Materials and methods
2.1. Materials
Monosialylganglioside (GM1) was purchased from Chongqing
Huanrui Biology Technology Co, Ltd (Chongqing, China).
Epirubicin∙HCl (EPI, purity 99.0% by high-performance liquid
chromatography) was received from Olympic Star Pharmaceu-
tical Co, Ltd (Shenzhen, China). Hydrogenated soy
phosphatidylcholine (HSPC) was obtained from Lucas
Meyer (Düsseldorf, Germany). 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene glycol)-
2000] (mPEG2000–DSPE) was purchased from Shanghai
Advanced Vehicle Technology Pharmaceutical Ltd (Shanghai,
People’s Republic of China). Cholesterol (CH) was obtained from
China National Medicines Co, Ltd (Shenyang, China). ZB-1 cation
exchange fibres were acquired from Guilin Zhenghan Tech-
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nology Development Co, Ltd (Guilin, China). All other chemicals
used in this study were of analytical or HPLC grade.
2.2. Animals
The male Wistar rats with the age of 7–8 weeks (weight, 180–
220 g) were purchased from the Laboratory Animal Center of
Shenyang Pharmaceutical University (Shenyang, China). All rats
had free access to food and water. The animal care and ex-
periments were performed in accordance with the guidelines
of the local AnimalWelfare Committee and Guide for the Care
and Use of Laboratory Animals [23].
2.3. Preparation of liposomes
Liposomes were prepared by using the modified ethanol in-
jection method [12,24]. Briefly, the lipid mixture (see Table 1)
was dissolved in absolute ethanol and then evaporated at 65 °C
to near dryness. The resulting dry lipid film was hydrated at
65 °C for 20 min in citrate buffer (pH 4.0) under mechanical agi-
tation to achieve a final lipid concentration of 50 mg/ml. After
hydration, the obtained multilamellar vesicles (MLV) was soni-
cated using a laboratory ultrasonic cell pulverizer (JY92-II;
Ningbo Scientz Biotechnology Co, Ltd, Ningbo, China) for at least
one 2-min cycle (200 W) and an additional 6-min cycle (400 W).
The suspension was then successively filtered through 0.80-,
0.45-, and 0.22-μm filter membranes at 25 °C to remove large
particles. The mean diameters and zeta potentials of lipo-
somes were determined by NICOMP 380 HPL submicron particle
analyser (Particle Sizing System, CA, USA).
2.4. Drug loading and determination of encapsulation
efficiency (EE)
EPI was loaded into liposomes by using a pH gradient method.
Briefly, a transmembrane pH gradient (ΔpH = 3) was estab-
lished by adding sodium phosphate solution (0.5 M) into the
suspension of empty liposomes. Subsequently, EPI solution
(4 mg/ml) and empty liposomes were mixed at a ratio of 1:10
(wt/wt) between the drug and lipid, and then the mixture was
incubated for 20 min at 60 °C.
After the drug was loaded, the untrapped EPI was removed
using a cation exchange fibre column to determine the en-
capsulation efficiency (EE). Briefly, 100 μl of samples were loaded
onto a 732 cation exchange resin mini-column (10 × 25 mm)
and then eluted with distilled water. The eluate was solubi-
lized with 90% (v/v) isopropyl alcohol containing 0.75 mol/l HCl,
and the concentration of EPI in the liposomal samples was as-
sessed photometrically at 480 nm (UV-1801 UV/VIS
spectrophotometer; Beijing Rayleigh Analytical Instrument Co,
Ltd, Beijing, China). The per cent EE was calculated as the per-
centage of EPI remaining in the liposomes following elution.
2.5. In vitro release assay
EPI solution or loaded liposomes were transferred to dialysis
bags. Drug release experiments were performed by dialysis
against 120 ml of the release buffer (300 mM xylitol, 80 mM
NH4Cl and 10 mM histidine, pH 7.4). A volume of 1 ml of EPI
solution or loaded liposomes was placed in dialysis bag (10 KDa
MWCO) at 37 °C. At various time points, aliquots were with-
drawn and stored at −20 °C until analysis. The concentration
of EPI was measured using a microplate reader fluorescence
spectrophotometer (Molecular Devices Ltd., USA).The emission/
excitation wavelengths of EPI were 502/562 nm.
2.6. Pharmacokinetics and biodistribution of liposomes in
vivo
Male Wistar rats were randomly divided. For the first injec-
tion, theWistar rats were initially administered with GM1molar
modified PEGylated liposomal EPI via the tail vein at a dose
of 1 μmol phospholipids/kg or 5% glucose solution instead of
the liposomes. Seven days later, the serum samples were col-
lected 30 minutes before the second injection. For the second
injection, GM1 modified PEGylated liposomal EPI was in-
jected intravenously at a dose of 5 μmol phospholipids/kg. At
0.083, 0.25, 0.5, 1, 2, and 4 h following intravenous injection,
blood samples were collected in a volume of 250 μl by eye punc-
ture. After withdrawing the last blood sample at 4 hours, the
liver and spleen were excised, rinsed in ice-cold normal saline,
and snap frozen. Blood samples were centrifuged at 4000 rpm
for 10min to isolate the plasma.The plasma and tissue samples
were stored at −20 °C until assayed. The detailed injection
scheme is presented in Table 2.
To investigate the effect of GM1 on the PEGylated lipo-
somes in the induction phase and the effectuation phase, the
detailed injection scheme is presented in Tables 3 and 4,
respectively.
2.7. Analytical procedure
To monitor the in vivo pharmacokinetic behaviour of lipo-
somes, the concentrations of EPI in plasma and tissue samples
were assayed by using a spectrofluorometric method. The
tissues were homogenized by using a Tissue-Tearor equipped
with an 80 mm probe (IKAWORKS GUANGZHOU, Guangzhou,
China). Before EPI analysis, the samples were treated as follows:
Table 1 – Compositions and characterizations of the prepared liposomes.
Formulation Compositions Size (nm) Zeta potentials
(mV)
Entrapment
efficacy (%)
EPI-PL(0.0% mol GM1) HSPC:CH:mPEG2000–DSPE:GM1 (3:1:1:0.0, wt/wt) 109.1 ± 1.6 −28.1 ± 2.1 97.4 ± 3.1
EPI-PL(2.5% mol GM1) HSPC:CH:mPEG2000–DSPE:GM1 (3:1:1:0.3, wt/wt) 106.8 ± 7.4 −32.1 ± 3.4 96.2 ± 2.4
EPI-PL(5.0% mol GM1) HSPC:CH:mPEG2000–DSPE:GM1 (3:1:1:0.6, wt/wt) 100.9 ± 1.4 −33.4 ± 1.9 97.2 ± 3.6
EPI-PL(10% mol GM1) HSPC:CH:mPEG2000–DSPE:GM1 (3:1:1:1.2, wt/wt) 101.8 ± 3.5 −38.1 ± 3.7 95.1 ± 4.2
EPI-PL(15% mol GM1) HSPC:CH:mPEG2000–DSPE:GM1 (3:1:1:1.8, wt/wt) 105.5 ± 2.3 −39.5 ± 3.6 95.3 ± 1.8
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3.9 and 3.8 ml extraction solutions (methanol/water, 50/50 con-
taining 0.3 M HCl, v/v) were added to 0.1 ml plasma and 0.2 ml
tissue homogenate, respectively.Themixture was then vortexed
for 5 min, and centrifuged at 10,000 rpm for 10 min. The su-
pernatant was transferred to another 7.0 ml-Eppendorf tube,
and centrifuged at 10,000 rpm for another 10 min.The final su-
pernatant was added into 96-well plates and assayed using a
microplate reader fluorescence spectrophotometer (Molecu-
lar Devices Ltd., USA).The emission/excitation wavelengths of
EPI were 502/562 nm.
2.8. Detection of anti-PEG IgM antibodies
mPEG2000–DSPE, at a concentration of 0.2 mmol/l, was added
to the wells of a 96-well plate (Corning Incorporated, NewYork,
USA) and the coated plate was thoroughly air dried. Tris-
buffered saline (50mM) containing 0.14mMNaCl and 1% bovine
serum albumin (BSA) was added to block the wells, and the
plate was incubated for 60 min.After incubation, the wells were
washed 3 times with 0.05% CHAPS in Tris-buffered saline (pH
8.0). Then, 100 μl of the diluted serum samples (1% BSA, 0.05%
CHAPS, 50 mMTris, pH 8.0) were added into the 96-well plate,
which was incubated for 60 min and washed 5 times as de-
scribed above. Horseradish peroxidase (HRP)-conjugated
antibody (100 μl, 1 μg/ml, rabbit anti-rat IgM–HRP conjugate) was
added to each well, and the wells were washed 5 times after
incubation for 60 min as described above. The coloration was
initiated by using 100 μl of o-phenylenediamine (1 mg/ml,
Sigma–Aldrich, St. Louis, MO, USA). After the wells were incu-
bated for 15 min, the reaction was stopped by the addition of
100 μl 2N sulphuric acid (H2SO4). The absorbance was mea-
sured at 490 nm by using a microplate reader fluorescence
spectrophotometer (Bio-Rad Laboratories Ltd., Hertfordshire,
UK). The experiment was performed at room temperature.
2.9. Statistical analysis
All data are presented as the mean ± standard deviation. Sta-
tistical comparisons were performed using Student’s t-test with
SPSS 17.0 software. P-values lower than 0.05 were considered
statistically significant.
Table 2 – The injection scheme of the various liposomes.
Groups First injection (1 μmol
phospholipids/kg)
Second injection (5 μmol
phospholipids/kg)
ABC
index(0–30 min)
A1 5% Glucose injection EPI-PL(0.0% mol GM1) /
B1 5% Glucose injection EPI-PL(2.5% mol GM1) /
C1 5% Glucose injection EPI-PL(5.0% mol GM1) /
D1 5% Glucose injection EPI-PL(10.0% mol GM1) /
E1 5% Glucose injection EPI-PL(15.0% mol GM1) /
A2 EPI-PL(0.0% mol GM1) EPI-PL(0.0% mol GM1) 0.067 ± 0.01
B2 EPI-PL(2.5% mol GM1) EPI-PL(2.5% mol GM1) 0.083 ± 0.02
C2 EPI-PL(5.0% mol GM1) EPI-PL(5.0% mol GM1) 0.120 ± 0.01
D2 EPI-PL(10.0% mol GM1) EPI-PL(10.0% mol GM1) 0.621 ± 0.05
E2 EPI-PL(15.0% mol GM1) EPI-PL(15.0% mol GM1) 0.584 ± 0.07
Table 3 – The injection scheme of GM1 on PEGylated liposomes in the induction phase.
Groups First injection (1 μmol
phospholipids/kg)
Second injection (5 μmol
phospholipids/kg)
ABC
index(0–30 min)
PL-PL EPI-PL(0.0% mol GM1) EPI-PL(0.0% mol GM1) 0.067 ± 0.01
2.5GPL-PL EPI-PL(2.5% mol GM1) EPI-PL(0.0% mol GM1) 0.096 ± 0.03
5.0GPL-PL EPI-PL(5.0% mol GM1) EPI-PL(0.0% mol GM1) 0.128 ± 0.01
10.0GPL-PL EPI-PL(10.0% mol GM1) EPI-PL(0.0% mol GM1) 0.628 ± 0.08
15.0GPL-PL EPI-PL(15.0% mol GM1) EPI-PL(0.0% mol GM1) 0.591 ± 0.03
Abbreviation: PL, EPI-PL (0.0% mol GM1); 2.5GPL, EPI-PL (2.5% mol GM1); 5.0GPL, EPI-PL (5.0% mol GM1); 10.0GPL, EPI-PL (10.0% mol GM1); 15.0GPL,
EPI-PL (15.0% mol GM1).
Table 4 – The injection scheme of GM1 on PEGylated liposomes in the effectuation phase.
Groups First injection (1 μmol
phospholipids/kg)
Second injection (5 μmol
phospholipids/kg)
ABC
index(0–30 min)
PL-PL EPI-PL(0.0% mol GM1) EPI-PL(0.0% mol GM1) 0.067 ± 0.01
PL-2.5GPL EPI-PL(0.0% mol GM1) EPI-PL(2.5% mol GM1) 0.095 ± 0.04
PL-5.0GPL EPI-PL(0.0% mol GM1) EPI-PL(5.0% mol GM1) 0.192 ± 0.02
PL-10.0GPL EPI-PL(0.0% mol GM1) EPI-PL(10.0% mol GM1) 0.301 ± 0.01
PL-15.0GPL EPI-PL(0.0% mol GM1) EPI-PL(15.0% mol GM1) 0.523 ± 0.06
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3. Results and discussion
3.1. The characteristics of the liposomes
In the present study, liposomal EPI was prepared by a pH gra-
dient.The mean particle sizes of the prepared liposomes were
90–110 nm. Zeta potentials demonstrated that all the lipo-
somes were negatively charged, from −20 to −40 mV. Moreover,
for all formulations, the per cent encapsulation efficiency (%EE)
of EPI in the prepared liposomes was over 95%. Details with
regard to the pharmaceutical properties of the prepared lipo-
somes are summarized in Table 1.
3.2. In vitro release assay
As seen in Fig. 1, in vitro release experiments, free EPI could
completely permeate the dialysis bag at 6 h, while only a small
amount of drug leaked from the liposomal preparations. In ad-
dition, there was no significant difference in drug release rate
among various GM1 molar content modified PEGylated lipo-
somal EPI (P > 0.05). This result suggested EPI stayed stable in
the liposomes and was suitable a marker for studying the phar-
macokinetics of liposomal preparations.
3.3. Pharmacokinetics of the first intravenous injection of
PEGylated liposomal EPI containing various GM1 molar
modifications
The rats were administrated with the PEGylated liposomal EPI
containing various GM1 molar modifications by intravenous
injection via the tail vein at a dose of 5 μmol phospholipids/
kg, and the pharmacokinetics was determined by using a
spectrofluorometric method. Fig. 2A showed that the circula-
tion time of the GM1 modified PEGylated liposomal EPI was a
little shorter than that without GM1. On one hand, it may be
ascribed to the changed conformation of the PEGylated lipo-
somes due to the addition of GM1. For a 100 nm-liposomal
particle grafted with DSPE–PEG2000, PEG chains should be ar-
ranged in the mushroom mode in the presence of <4 mol%
DSPE–PEG2000, while in the transition mode with a 4–8 mol%
modification, and in the brush mode with >8 mol% PEGylation
[25,26]. Thus, in the present study, depending on the 5 mol%
DSPE–PEG2000 modification, brush and mushroommode tran-
sition states would have coexisted, which is expected to be the
most stable state, and prevented opsonin uptake [27]. GM1, the
hydrophilic surfactant molecule, would convert the coexist-
ing brush and mushroommode transition state to brush mode
alone in space conformation, or increase the ratio of brushmode
in the two coexisting states, resulting in the reduction in com-
pliance on the liposome surface. On the other hand, after GM1
modified on PEGylated liposomes, the head of this molecule
surfactants would take up part of the surface of the lipo-
somes, which would lower the coverage of PEG. GM1 consists
of four monosaccharides, and the compliance and hydrophi-
licity of the component oligosaccharide chains are lower than
that of DSPE–PEG2000 chain.The two factors contributed to the
weaker regulatory effect of PEGylated liposomes with GM1
Fig. 1 – In vitro release of PEGylated liposomal EPI
containing various molar GM1 modifications. Date
represented as Mean ± SD, n = 3.
Fig. 2 – The pharmacokinetic and tissue distribution of PEGylated liposomal EPI containing various molar GM1
modifications. From groups A1 to E1 represented pre-dosing with 5% glucose injection, while A2 to E2 represented the
effect of repeated injection of PEGylated liposomal EPI containing various molar GM1 modifications on the ABC
phenomenon in rats. (A) Blood clearance. (B) Hepatic and splenic accumulation 4 h after intravenous injection of single
injection and repeated injection. Data are shown as Mean ± SD, n = 3.
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modification than without GM1modification, thus correspond-
ing to a shorter circulation time in vivo. Dexi Liu has introduced
that rats have naturally occurring anti-GM1 antibody which
induces rapid clearance of GM1-modified liposome [28]. The
presence of such antibody would make complication on un-
derstanding the results in my study. So in rats, single and
repeated only GM1-modified liposome would not change the
circulation time and uptake by the MPS respectively in the study
(data not shown), which proved that there were no anti-GM1
antibodies in the rats we had used in this study.
3.4. Effect of repeated injection of PEGylated liposomal
EPI containing various molar GM1 modifications on the ABC
phenomenon
The effect of GM1 with various molar content modifications
on the PEGylated liposomal EPI on inducing the ABC phenom-
enon after repeated injection was investigated. As illustrated
in Fig. 2A and 2B, the GM1 molar concentrations of the
PEGylated liposomes on the first injection were 2.5%, 5.0%,
10.0%, and 15.0%, respectively. Although, all the prepared li-
posomes caused the ABC phenomenon in the repeated
intravenous injection, there were significant differences in the
extent of the ABC phenomenon. When the molar concentra-
tions of GM1 were 2.5% and 5.0%, the EPI concentrations in the
blood decreased significantly at the first time point after in-
jection, which presented severe ABC phenomenon and there
was no significant difference in the comparison with lipo-
somes without GM1. When the GM1 molar concentration
reached 10.0% and 15.0%, the EPI concentrations in the blood
decreased slowly and the ABC phenomenon of the second in-
jection reduced by about 50%, compared with the PEGylated
liposomal EPI alone (P < 0.05).
3.5. Effect of GM1 on the PEGylated liposomal EPI in the
induction phase of the ABC phenomenon
To investigate the effect of GM1 on PEGylated liposomes in the
induction phase of the ABC phenomenon, the rats were
administered with various GM1 molar content modified
PEGylated liposomal EPI via the tail vein at a dose of 1 μmol
phospholipids/kg as the first injection. After 7 days, for the
second injection, PEGylated liposomal EPI was injected intra-
venously at a dose of 5 μmol phospholipids/kg. As shown in
Fig. 3A, when the modified GM1 content reached 10% and 15%
mol, the EPI in PEGylated liposomes decreased slowly in cir-
culation in vivo after the second injection. Compared to PL-PL
group (Fig. 3B), the accumulation of EPI in hepatic and splenic
significantly decreased (P < 0.05).
3.6. Effect of GM1 on the PEGylated liposomal EPI in the
effectuation phase of the ABC phenomenon
In order to survey the role of GM1 modifications on PEGylated
liposomal EPI in the effectuation phase, the rats were admin-
istered intravenously with PEG-modified liposomes as the first
injections. After 7 days, PEGylated liposomal EPI containing
various molar GM1 modifications served as second injection.
As shown in Fig. 4A and 4B, with the increasing GM1 content
in the second injections, the plasma pharmacokinetic profile
of EPI gradually slowed down.When the content was 15%, its
pharmacokinetic profile and hepatosplenic distribution pre-
sented the most significant difference (P < 0.05, compared with
PL-PL).
3.7. Comparison of the ABC index of the GM1 modified
PEGylated liposomal EPI following repeated injections
Ishihara et al. [29] used the ABC index, the ratio of the area
under the concentration–time curve from time 0 to the last
measured time point (AUC0–t) for the second injection to that
of the first injection, as a parameter to evaluate the ABC phe-
nomenon. A higher index indicates a slower clearance of
PEGylated nanocarriers from the blood circulation and a weaker
induction of the ABC phenomenon. In this study, the ratio of
AUC(0–30 min) was adopted to assess the ABC phenomenon. We
calculated the ratio for different periods (0–30 min, 0–1 h, 0–2 h,
and 0–4 h), which showed that the discrepancies in the ratio
Fig. 3 – Effect of GM1 on PEGylated liposomal EPI in the induction phase of the ABC phenomenon in rats. The control
represents no pre-dosing; 7 days later, the rats were given PEGylated liposomal EPI without GM1 modification. (A) Blood
clearance. (B) Hepatic and splenic accumulation 4 h after intravenous injection of the test dose. Data are shown as
Mean ± SD, n = 3, *P < 0.05, **P < 0.01, compared with 5% Glu-PL.
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did not change (data not shown). The results were similar to
the previous study in our group [30]. With the view that the
accelerated blood clearance effect lasted only a short time, so
the ABC index(0–30 min) was applied to evaluate the extent of the
ABC phenomenon. Table 2 demonstrated an increase in theABC
index(0–30 min) after different intravenous injection schemes. As
seen from the table, with the various GM1 molar modifica-
tions on PEGylated liposomal EPI on repeated injections, the
ABC index(0–30min) was the highest to the lowest as follows: 15.0%
GM1 modification > 10.0% GM1 modification > 5.0% GM1 modi-
fication > 2.5% GM1 modification. As demonstrated, when the
GM1modification reached 10.0% and 15.0%, theABC index(0–30min)
increased significantly (P < 0.05). In the study, the ABC phe-
nomenon in the induction phase showed a decrease in the
following order: 15.0GPL-PL > 10.0GPL-PL > 5.0GPL-PL > 2.5GPL-
PL > PL-PL. In the study, the ABC phenomenon in the
effectuation phase, showed a decrease in the following order:
PL-15.0GPL > PL-10.0GPL > PL-5.0GPL > PL-2.5GPL > PL-PL.
In the present study, after repeated injection of PEGylated
liposomal EPI, the administered dose of EPI was 0.08 mg per
kg by the 1 μmol phospholipids/kg as the first injection, which
would cause severe ABC phenomenon. As seen from the ac-
quired plasma curve drug and ABC index, when the
concentration of GM1 reached to 10% and 15% mol in the re-
peated injections of liposomes, the ABC phenomenon
significantly reduced.The results may be closely related to the
characteristics of GM1. GM1 is an amphipathic substance, con-
sists of a hydrophilic oligosaccharide chains and lipophilic
ceramide, wherein a sialic acid moiety is attached to the oli-
gosaccharide chains. Based on the accepted mechanism of the
ABC phenomenon, in the induction phase, PEGylated lipo-
somal EPI used in the first injection, which is regarded asT-cell
independent type 2 antigens (TI-2), stimulated the splenic mar-
ginal zone B cells to produce anti-PEG IgM, resulting in the
accelerated blood clearance of subsequently administered li-
posomes. In general, most TI-2 antigens with neat surface
arrangements are large multivalent molecules that exhibit a
prolonged circulation time in vivo [16]. Based on the common
property of TI-2 antigens, the interaction between the
antigens and membrane receptors in B cells and persistent
B-cell signalling induced an immune response after the re-
peated injection. The lipophilic portions of GM1 are inserted
within the phospholipid bilayer, and the hydrophilic oligosac-
charide chains on the surface of the bilayer on the PEGylated
liposomes.When the GM1 content modification on PEGylated
liposome surface reaches a certain level, the interaction between
the oxygen atom of the PEG chain and the hydroxyl group of
sialic acid on GM1 would result in changes in conformation
of PEGylated EPI liposomes, which would disrupt the TI-2
antigen characteristics. As introduced above, GM1 consists of
four monosaccharides, including sialic acid. It has been re-
ported that GM1 can reduce the immunogenicity of themodified
liposomes [31]. Michalek et al. [31] reported that GM1, when
incorporated into the activating liposome membrane at molar
ratios between 10−2 and 10−5, inhibited activation in a dose-
dependent manner. They presented data that sialic acid is a
very efficient inhibitor of the alternative pathway of human
C, showing activity at molar concentrations as low as 0.01%.
In the present study, when the GM1 content modification on
PEGylated EPI liposomes surface reached 10 and 15% mol, the
conformation of liposomes would change,meanwhile a portion
of GM1 would be exposed to the liposome surface, which may
reduce the immunogenicity of themodified liposomes, and thus
weaken the ABC phenomenon on the repeated injection.While
the data that GM1 reduced immunogenicity of the modified
liposomes to reduce the ABC phenomenon was not suffi-
cient, the mechanism needed further study.
3.8. Comparison of anti-PEG IgM produced by the
PEGylated liposomal EPI containing various GM1 molar
modifications
It has been reported that there is a positive correlation between
anti-PEG IgM production and the strength of the ABC phe-
nomenon caused by PEGylated liposomes [32]. To investigate
whether the GM1 would influence the production of anti-PEG
IgM, the anti-PEG IgM level in the serum was assessed on day
7 after the initial intravenous dose of PEGylated liposomes
Fig. 4 – Effect of GM1 on PEGylated liposomal EPI in the effectuation phase of the ABC phenomenon in rats. The control
represents no pre-dosing; 7 d later, the rats were given PEGylated liposomal EPI without GM1 modification. (A) Blood
clearance. (B) Hepatic and splenic accumulation 4 h after intravenous injection of the test dose. Data are shown as
Mean ± SD, n = 3, *P < 0.05, **P < 0.01, compared with 5% Glu-PL.
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containing various GM1modifications.Accordingly, in this study,
the IgM antibody reactive to the PEG on the PEGylated lipo-
somes was quantized using classical ELISA [33–35].As illustrated
in Fig. 5, the absorbance ratio in the rank order of the highest
to the lowest was as follows: 2.5% GM1modification > 5.0% GM1
modification > 10.0% GM1 modification > 15.0% GM1 modifi-
cation. The results indicated that the induction of the ABC
phenomenon was accompanied by an increase in the anti-
PEG IgM level.
The production of anti-PEG IgM was detected following the
first injection of the different GM1 modifications on the
PEGylated liposomes.We found that with the increase content
modification of GM1, the production of anti-PEG IgM reduced,
which also verified the above view that GM1 would disturb the
neat conformation, and disrupt the TI-2 antigen characteris-
tics. Recent studies also have shown that in PEG-conjugates
such as DSPE–PEG2000, the connecting portion between the hy-
drophilic PEG chain and the hydrophobic segments may be the
key sites for anti-PEG IgM to recognize PEG modified formu-
lations.Yokoyama et al. [17] revealed that anti-PEG IgM seemed
to recognize the interface between the hydrophilic PEG chain
and hydrophobic block of PEG-conjugates, which mediated the
accelerated blood clearance, rather than recognize the PEGmain
chain.We chose GM1 modification on the liposomes with PEG,
which masked the hydrophobic connecting portion of PEG–
DSPE on the modified liposomes.Then PEGylated liposomal EPI
was injected in rats as the first injection, and various GM1molar
content modifications on PEGylated liposomal EPI were intra-
venously administrated to verify the effect of GM1 in the
effectuation phase. As illustrated in Fig. 4A and 4B, the rats ac-
quired the same amount of anti-PEG IgM for the first injection
in vivo, and after injection of GM1 modified PEGylated lipo-
somes, the ABC phenomenon reduced with increasing GM1
modification. The results demonstrated that GM1 could mask
the hydrophobic connecting portion of PEG–DSPE on the modi-
fied liposomes, which would attenuate the ABC phenomenon.
4. Conclusion
In this study, GM1 with various molar concentrations wasmodi-
fied on the PEGylated liposomal EPI, and the effect of GM1 on
abrogating or attenuating the ABC phenomenon of PEGylated
liposomal EPI was investigated, such as their pharmacoki-
netic behaviour and tissue distribution after the second dose
inWistar rats. Results showed that when GM1 contents reached
10% or 15% mol, the ABC phenomenon of the PEGylated lipo-
somal EPI significantly reduced.We also found that GM1 played
an important role in abrogating the ABC phenomenon in both
the induction phase and the effectuation phase. GM1 modi-
fication on PEGylated liposomes may provide a significant
improvement in clinical practice of PEGylated liposomes.
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